SUPPORTING INFORMATION

Table S1. Body Weight (g) of SHRs and WNRs after Oral Administration of MAHP

	0	1st	2nd	3rd	4th	5th	+1
200WT	334.07 ± 4.16	342.52 ± 3.86	350.13 ± 4.22	359.74 ± 4.82	364.78 ± 4.98	368.84 ± 4.92	379.27 ± 3.51
200MAHP	343.06 ± 4.50	352.65 ± 4.18	360.39 ± 4.34	365.87 ± 4.19	370.04 ± 3.84	374.58 ± 3.74	380.31 ± 3.63
50WT	306.58 ± 1.06	309.60 ± 1.47	315.24 ± 1.86	319.46 ± 3.37	320.44 ± 3.42	325.05 ± 3.95	332.13 ± 5.18
50MAHP	303.76 ± 3.23	306.64 ± 2.52	314.84 ± 1.64	317.37 ± 1.54	322.09 ± 2.37	329.76 ± 2.67	336.66 ± 2.64

Table S2. Tissue Weight (g) of SHRs and WNRs after Oral Administration of MAHP

	heart	stomach	liver	spleen	kidney	brain
200WT	1.35 ± 0.10	1.44 ± 0.04	9.89 ± 0.56	0.69 ± 0.02	2.45 ± 0.09	2.14 ± 0.03
200MAHP	1.25 ± 0.02	1.35 ± 0.03	8.42 ± 0.16	0.65 ± 0.00	2.32 ± 0.04	2.11 ± 0.01
50WT	1.29 ± 0.19	1.36 ± 0.21	9.18 ± 1.43	0.64 ± 0.10	2.38 ± 0.36	1.88 ± 0.29
50MAHP	1.31 ± 0.04	1.37 ± 0.05	9.00 ± 0.19	0.61 ± 0.02	2.16 ± 0.16	1.82 ± 0.09



Supplementary Figure 1. Mass spectrometric analyses of the MAHPs products that digested by trypsin in vitro.

(A) The sequence ALPMHIR was identified. (B) The sequence DKIHPFQR was identified.



Supplementary Figure 2. Mass spectrometric analyses of the MAHPs products that digested by trypsin in vitro.

(A) The sequence FFVAPFPEVFGK was identified. (B) The sequence IPPKVLPVPEQR was identified.



Supplementary Figure 3. Mass spectrometric analyses of the MAHPs products that digested by trypsin in vitro.

(A) The sequence LKPNM was identified. (B) The sequence VPPQRRPLKPWQR was identified.



Supplementary Figure 4. Mass spectrometric analyses of the MAHPs products that digested by trypsin in vitro.

(A-B) The sequence YLAHKALPMHIR was identified.



Supplementary Figure 5. Mass spectrometric analyses of the MAHPs products that digested by trypsin in vitro.

The sequence YQQPVLQR was identified.